Vir Biotechnology
212 hedge funds and large institutions have $2.2B invested in Vir Biotechnology in 2022 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 75 increasing their positions, 57 reducing their positions, and 41 closing their positions.
74% more call options, than puts
Call options by funds: $11.6M | Put options by funds: $6.66M
43% more capital inflows, than outflows
Capital inflows: $371M | Capital outflows: $260M
32% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 57
24% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 41
4% more funds holding
Funds holding: 204 → 212 (+8)
3.51% more ownership
Funds ownership: 61.33% → 64.84% (+3.5%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$173M |
| 2 |
State Street
Boston,
Massachusetts
|
+$30.9M |
| 3 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$18.3M |
| 4 |
Morgan Stanley
New York
|
+$11.4M |
| 5 |
Renaissance Technologies
New York
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$94.8M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$39M |
| 3 |
TAMH
Taikang Asset Management (HK)
Hong Kong
|
-$13.7M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$11.6M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$8.46M |
VIR Hedge Fund Activity: Q2 2022 in Review
212 of the 5,962 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q2 2022, worth a combined $2.2B — up 5.4% from $2.09B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new VIR positions and 41 closed out — a net gain of 10 holders — while 75 added to existing stakes and 57 trimmed.
The largest buyer was BlackRock, adding an estimated $173M. The largest seller was Millennium Management, cutting an estimated $94.8M.
- 212 institutional investors held Vir Biotechnology (VIR) as of Q2 2022, up from 204 in Q1 2022.
- Funds reported $2.2B of Vir Biotechnology stock for Q2 2022, up 5.4% quarter-over-quarter.
- 51 funds opened new Vir Biotechnology positions in Q2 2022 and 41 closed out, a net change of +10 holders.
- The largest Vir Biotechnology buyer in Q2 2022 was BlackRock, an estimated $173M added.
- The largest Vir Biotechnology seller in Q2 2022 was Millennium Management, an estimated $94.8M sold.
Based on aggregated 13F filings for Q2 2022.